The Company wishes to inform shareholders that it was notified by the United States Patent and Trademark Office that US Patent Application 16/991812 – Host Defense Protein Mimetics for Prophylaxis And/Or Treatment of Inflammatory Bowel Diseases of the Gastrointestinal Tract – was allowed for issuance as a patent. The claims allowed include Brilacidin treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis and Ulcerative Colitis.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IPIX:
- Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
- BT BeaMedical, Shina Systems enter strategic development agreement
- Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement